UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 転移性ホルモン受容体陽性乳癌に対する治療アプローチ：内分泌療法 treatment approach to metastatic hormone receptor positive breast cancer endocrine therapy
- 2. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer
- 3. 乳癌予防のための選択的エストロゲン受容体調節因子およびアロマターゼ阻害剤 selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention
- 4. アロマターゼ阻害剤による骨量減少の評価およびマネージメント evaluation and management of aromatase inhibitor induced bone loss
- 5. がん予防 cancer prevention
English Journal
- New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
- Hole S1, Pedersen AM1, Hansen SK1, Lundqvist J2, Yde CW1, Lykkesfeldt AE1.
- International journal of oncology.Int J Oncol.2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.
- Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will
- PMID 25625755
- Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review.
- Behan LA1, Amir E, Casper RF.
- Menopause (New York, N.Y.).Menopause.2015 Mar;22(3):342-50. doi: 10.1097/GME.0000000000000426.
- OBJECTIVE: The increasing incidence of breast cancer (BC) worldwide has resulted in widespread interest in primary prevention therapies. A number of large randomized trials have shown that selective estrogen receptor modulators can reduce the relative risk for BC by 30% to 40% in high-risk women. In
- PMID 25692874
- Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.
- Aktas B1, Sorkin M, Pusztai L, Hofstatter EW.
- European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP).Eur J Cancer Prev.2015 Feb 26. [Epub ahead of print]
- Despite their efficacy, uptake of selective estrogen receptor modulators for breast cancer chemoprevention remains low. Exemestane, an aromatase inhibitor, has recently been identified as a potential chemopreventive option with fewer serious side effects compared with selective estrogen receptor mod
- PMID 25642790
Japanese Journal
- 新規非可逆的アロマターゼ阻害薬エキセメスタン(アロマシン^【〇!R】)の\薬理学的特性および臨床効果
- 日本薬理学雑誌 122(4), 345-354, 2003-10-01
- NAID 130000085914
Related Links
- Take an active role in your breast cancer treatment plan with downloadable tools designed for patients taking AROMASIN These resources will help you get the most out of your therapy and help you save on your monthly AROMASIN ...
- アロマシンとは。効果、副作用、使用上の注意。女性ホルモンのエストロゲンの生成を抑える作用があり、閉経後の乳ガンの治療に用いられる薬です。 エキセメスタン製剤は、1日1回の服用で、高齢者にも高い安全性を示す薬です。
Related Pictures
